Skip to content

Psychosexuological Interventions to Support Sexual Function in Breast Cancer Patients

Psychosexuological Interventions to Support Sexual Function in Breast Cancer Patients

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06327607
Enrollment
82
Registered
2024-03-25
Start date
2023-06-09
Completion date
2024-12-31
Last updated
2024-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Brief summary

Prospective pilot study on the feasibility and efficacy of a brief psychosexual support intervention in breast cancer patients undergoing hormonal therapies for at least 6 months. The study is randomized in the two following arms: Control arm (standard care pathway) Psychosexual intervention arm

Detailed description

The aim of the study is to evaluate the effectiveness of a psychosexual intervention on sexual functioning, mood (levels of depression and anxiety), sleep, and quality of life, compared to standard care pathway. Considering the high incidence of sexual dysfunction in breast cancer patients, this study will focus on this population of patients. The psychosexual intervention aims to improve female sexual functionality and satisfaction by facilitating the understanding of disorders, enabling adequate assessment of possible interventions, and adopting specific treatment exercises. Patients will be randomized in one of the following two arms: Control arm (standard care pathway) Psychosexual intervention arm

Interventions

OTHERControl Group

Standard care for breast cancer

OTHERPsychosexological intervention

The intervention will be conducted individually and will take place once a week for one hour, for a total of 8 consecutive weeks, which must be completed within a maximum duration of 10 weeks.

Sponsors

European Institute of Oncology
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Women with age \>=18 years; * Breast cancer patients undergoing hormonal therapy for at least 6 months in accordance with clinical practice and scientific evidence; * Pre-menopausal patients (regular menstrual cycles in the last year) before the start of oncological treatments; * Presence of one or more criteria of sexual dysfunction as per DSM-5; * Acceptance and signature of the Informed Consent.

Exclusion criteria

* Patients in postmenopausal status; * Presence of psychiatric or neurological conditions that impair the ability to perform the exercises proposed by the research project; * Already undergoing psycho-sexual counseling; * Refusal to sign the informed consent

Design outcomes

Primary

MeasureTime frameDescription
Evaluation of differences between two arms in female sexual satisfaction and functionality scores10 weeksMeasurement of the differences between the two groups in female sexual satisfaction and functionality scores before and after participation in the psychosexual intervention group, we will use the Brief Index of Sexual Functioning-Woman (BISF-W). This is a self-administered questionnaire specifically designed to assess female sexual functionality and satisfaction.

Secondary

MeasureTime frameDescription
Evaluation of differences between two arms in levels of quality of life10 weeksTo measure the differences between the two arms in levels of quality of life investigated using the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 questionnaire.
Evaluation of differences between two arms in levels of anxiety and depression10 weeksLevels of anxiety and depression measured using the Hospital Anxiety and Depression Scale (HADS).
Evaluation of differences between two arms in levels of sleep quality10 weeksLevels of sleep quality measured using the Pittsburgh Sleep Quality Index (PSQI) questionnaire.

Countries

Italy

Contacts

Primary ContactGabriella Pravettoni
gabriella.pravettoni@ieo.it+390257489731

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026